drugset / Trial / NCT00812825

A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers

NCT00812825

Phase 1 Completed 78 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics (how the drug effects certain target sites of activity in the body) of escalating doses of oral PF-04171327 in healthy volunteers for 14 days (Part 1). Part 2 will evaluate the pharmacokinetics of a single 10 mg dose of the PF-04171327 tablet in healthy volunteers.

Timeline

Start
2009-01
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisolone Other / unclassified 5 mg Oral
Comparator Prednisolone Other / unclassified 10 mg Oral
Comparator Prednisolone Other / unclassified 20 mg Oral
Subject fosdagrocorat Small molecule 1 mg Oral
Subject fosdagrocorat Small molecule 3 mg Oral
Subject fosdagrocorat Small molecule 10 mg Oral
Subject fosdagrocorat Small molecule 30 mg Oral

Indications

No indication recorded.